Efficacy and Safety of Mizoribine for the Treatment of Refractory Nephrotic Syndrome: Protocol for a Multicenter, Controlled, Open-label, Randomized Controlled Trial

Zheyi Dong   ^{1, 2, 3, 4, 5} , MD ;   Jianhui Zhou   ^{1, 2, 3, 4, 5} , MD ;   Zhonggao Xu   ⁶ , MD ;   Zhaohui Ni   ⁷ , MD ;   Yani He   ⁸ , MD ;   Hongli Lin   ^{9, 10} , MD ;   Gengru Jiang   ¹¹ , MD ;   Xuefeng Sun   ^{1, 2, 3, 4, 5} , MD ;   Li Zhang   ^{1, 2, 3, 4, 5 *} , MD ;   Xiangmei Chen   ^{1, 2, 3, 4, 5 *} , MD

¹ Department of Nephrology, First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China

² Nephrology Institute of the Chinese People's Liberation Army, First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China

³ State Key Laboratory of Kidney Diseases, First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China

⁴ National Clinical Research Center for Kidney Diseases, First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China

⁵ Beijing Key Laboratory of Kidney Disease Research, First Medical Center of Chinese People's Liberation Army General Hospital, Beijing, China

⁶ The First Hospital of Jilin University, Changchun, China

⁷ Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

⁸ Daping Hospital, Army Medical University, Chongqing, China

⁹ Key Laboratory of Kidney Disease, The First Affiliated Hospital of Dalian Medical University, Dalian, China

¹⁰ The Center for the Transformation Medicine of Kidney Disease, The First Affiliated Hospital of Dalian Medical University, Dalian, China

¹¹ XinHua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China

*these authors contributed equally